Navigation Links
Soligenix Announces Formation of Oral Mucositis Medical Advisory Board
Date:2/4/2013

er therapy. Research in oral mucositis management has focused on topical anti-infectives (defensins), growth factors and cytokines (KGFs and IL-11), cytoprotective agents (benzydamine, amifostine), and low level lasers therapy. Additional research interests include basic research and management strategies for other oral complications of cancer therapy including salivary gland dysfunction, oral graft-versus-host disease in allogeneic hematopoietic cell transplant recipients, and dental growth and development problems following hematopoietic cell transplant. Additionally, Dr. Schubert has been involved with research related to oral changes and infections in HIV-infected patients.  Dr. Schubert received his Doctor of Dental Surgery from the University of Washington, where he completed a residency in Hospital Dentistry, and later received his Masters of Dental Sciences degree from the University of Washington.

About SGX942

SGX94 is an IDR, a new class of short, synthetic peptides that has a novel mechanism of action in that it has simultaneous anti-inflammatory and anti-infective activity. IDRs have no direct antibiotic activity but modulate host responses, increasing survival after infections with a broad range of bacterial Gram-negative and Gram-positive pathogens, as well as accelerating resolution of tissue damage following exposure to a variety of agents including bacterial pathogens, trauma and chemo- and/or radiation-therapy.  SGX94 has demonstrated safety in a Phase 1 clinical study in healthy human volunteers and efficacy in numerous animal disease models including mucositis, colitis, skin infection and other bacterial infections.  SGX94 is the subject of an open Investigational New Drug (IND). SGX94 was developed pursuant to discoveries made by Professors B. Brett Finlay , PhD and Robert Hancock , PhD of the University of British Columbia, Canada and approximately $40 mill
'/>"/>

SOURCE Soligenix, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Soligenix Announces Further Progress with ThermoVax™ for Long-Term Vaccine ThermoStability
2. Soligenix Reports First Quarter 2012 Financial Results and Highlights Recent Accomplishments
3. Soligenix Reports Second Quarter 2012 Financial Results and Highlights Recent Accomplishments
4. Soligenix Announces Issuance of US Patent for Topically Active Steroids to Treat Inflammatory Gastrointestinal Disorders
5. FDA Grants Soligenix Fast Track Designation for SGX203 for the Treatment of Pediatric Crohns Disease
6. Soligenix Reports Third Quarter 2012 Financial Results and Highlights Recent Accomplishments
7. FDA Grants Soligenix Fast Track Designation for OrbeShield(TM) for the Reduction of Mortality Associated with Gastrointestinal Acute Radiation Syndrome (GI ARS)
8. Precision Optics Corporation Announces $1 Million Order for Microprecision™ Based Endoscopes
9. Young Innovations, Inc. Announces Record Sales and EPS for the Quarter Ended March 31, 2012
10. JDRF Announces Research Collaboration with Dexcom, Inc. to Develop "Smart Transmitter" Technology to Accelerate Artificial Pancreas Studies
11. Misonix Announces New Distribution Agreement For Panama
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/2/2015)...   Oriel STAT A MATRIX announces ... most critical compliance and performance issues in the ... are experiencing an industry-transforming level of demand and ... global supply chains are negatively impacting product quality ... regulators are increasing compliance requirements, scrutiny, and enforcement. ...
(Date:3/2/2015)... 2, 2015  Akron Children,s Hospital has been designated ... American College of Radiology (ACR), making it the first ... second children,s hospital in the United States ... "Earning recognition from the ACR as a DICOE provides ... level compared with national benchmarks," says Dr. Michael ...
(Date:3/2/2015)... and MENLO PARK, Calif. ... Pharmaceuticals, Inc. (OTCQX: DMPI) (DelMar and the ... proven cancer therapies in new orphan drug indications, ... Allowance from the U.S. Patent and Trademark Office ... Compositions and methods to improve the therapeutic benefit ...
Breaking Medicine Technology:Oriel STAT A MATRIX Announces New Professional Certification Programs for Medical Device Regulatory and Quality Assurance Professionals 2Oriel STAT A MATRIX Announces New Professional Certification Programs for Medical Device Regulatory and Quality Assurance Professionals 3Akron Children's designated ACR Diagnostic Imaging Center of Excellence 2DelMar Pharmaceuticals Receives Notice of Allowance of Fourth U.S. Patent Covering Methods of Use and Compositions for VAL-083 2DelMar Pharmaceuticals Receives Notice of Allowance of Fourth U.S. Patent Covering Methods of Use and Compositions for VAL-083 3DelMar Pharmaceuticals Receives Notice of Allowance of Fourth U.S. Patent Covering Methods of Use and Compositions for VAL-083 4
... NEW YORK, March 21, 2011 The Alzheimer,s Drug ... grant of $170,750 to ADispell Inc. to develop small ... loss that occurs with Alzheimer,s Disease. ... licensed technology from Cornell University to develop neuroprotective drug ...
... LLC , ( www.curemark.com ), a drug research and development ... the company has completed its targeted enrollment of Phase III ... Curemark has reached its targeted enrollment for the study ... CM-AT Phase III trial at 18 sites across the country. ...
Cached Medicine Technology:Alzheimer's Drug Discovery Foundation Supports ADispell Technology with a Grant to Advance Novel Drug Candidates for Alzheimer's Disease 2Curemark Completes Enrollment of Phase III Autism Trials 2
(Date:3/2/2015)... NY (PRWEB) March 02, 2015 ... Administration (FDA) warned against the use of power ... and fibroid removal surgeries, insurer UnitedHealthCare is poised ... use of those devices. In a notification sent ... beginning in April, it would require pre-authorization for ...
(Date:3/2/2015)... New York (PRWEB) March 02, 2015 ... of Idoll Magazine, a medium for the model agency ... can find, and buy Mango, Passion Fruit, Pink Grapefruit, ... March 3rd, 2015, after 1pm. , At a cost ... has recently came under fire by announcing the brands ...
(Date:3/2/2015)... Gummy smile reduction expert, Dr. Alex ... involve one or several procedures to reduce the appearance of ... a more even gum line. Dr. Farnoosh is the creator ... can permanently lighten discolored or naturally dark gums. , ... personalized treatment plan to address a patient’s specific needs based ...
(Date:3/2/2015)... Minnetonka, MN (PRWEB) March 02, 2015 ... accredited temperature calibration for Secondary Standard Platinum ... (RTDs) in 5 business days or less . ... is NVLAP ® Accredited (Lab Code 200706-0), ... NIST traceability. Temperature range is -196°C to ...
(Date:3/2/2015)... Over the last five years the ultrasound market ... expand their geographic presence and achieve economies of scale. ... billion by 2019 at CAGR of 5.1% from 2014 ... Canada and a major part of Europe are mature ... Asia-Pacific including China and India, Latin America and the ...
Breaking Medicine News(10 mins):Health News:Power Morcellator Lawyers at Bernstein Liebhard LLP Comment on Insurers’ Decision to Restrict Most Common Form of Hysterectomies 2Health News:Power Morcellator Lawyers at Bernstein Liebhard LLP Comment on Insurers’ Decision to Restrict Most Common Form of Hysterectomies 3Health News:Power Morcellator Lawyers at Bernstein Liebhard LLP Comment on Insurers’ Decision to Restrict Most Common Form of Hysterectomies 4Health News:Sex Sells! A Newly Minted Organic Bodycare Brand Courts Controversy at a Cost 2Health News:Gummy Smile Expert, Dr. Alex Farnoosh, is Now Offering Gum Reshaping Procedures 2Health News:Burns Engineering Announces Quick-Turn Temperature Calibrations 2Health News:Therapeutic Ultrasound Devices Market worth $6.2 Billion by 2019 - New Research Report by MarketsandMarkets 2Health News:Therapeutic Ultrasound Devices Market worth $6.2 Billion by 2019 - New Research Report by MarketsandMarkets 3
... a company developing breakthrough molecular imaging agents ... announced today that the United States Patent ... 7,438,891, covering methods of imaging cardiovascular plaque ... patent, exclusively licensed from the Massachusetts General ...
... Increased 2% and Increased 1% Excluding the Impact of Foreign ... Decreased 7% and Decreased 1% Excluding the Impact of Foreign ... Increase Led by Growth in Excess of 10% for Prevnar, ... Jan. 26 Wyeth (NYSE: WYE ) today ...
... Saint Joseph,s Health System announced,that it has launched ... a,non-profit training center for robotic surgical teams from around ... Thoracic Surgeons (STS) annual,meeting in San Francisco. , ... to patients from robotic-assisted,surgery since we began our program ...
... To Stay Happy and Healthy This WinterSAN JOSE, Calif., ... avoiding the "winter blues" is to set small goals, ... and exercising, for a well-rounded approach to life. This ... Day of the Year," January 26, 2009, designated by ...
... Jan. 26 Concentric Medical, Inc., the global leader ... today announced that the company,s Merci Retrieval System(TM) has ... in August 2004. The Merci Retrieval System is ... to remove blood clots from patients suffering an ischemic ...
... Internal Manufacturing Scale-Up Underway to Support Increased Product ... (OTC Bulletin Board: BLFS), a leading developer and ... media products for cells, tissues, and organs, today ... full year 2008 and also the receipt of ...
Cached Medicine News:Health News:FluoroPharma Obtains US Patent for Imaging Cardiovascular Plaque using FDG 2Health News:Wyeth Reports Earnings Results for the 2008 Full Year and Fourth Quarter 2Health News:Wyeth Reports Earnings Results for the 2008 Full Year and Fourth Quarter 3Health News:Wyeth Reports Earnings Results for the 2008 Full Year and Fourth Quarter 4Health News:Wyeth Reports Earnings Results for the 2008 Full Year and Fourth Quarter 5Health News:Wyeth Reports Earnings Results for the 2008 Full Year and Fourth Quarter 6Health News:Wyeth Reports Earnings Results for the 2008 Full Year and Fourth Quarter 7Health News:Wyeth Reports Earnings Results for the 2008 Full Year and Fourth Quarter 8Health News:Wyeth Reports Earnings Results for the 2008 Full Year and Fourth Quarter 9Health News:Wyeth Reports Earnings Results for the 2008 Full Year and Fourth Quarter 10Health News:Wyeth Reports Earnings Results for the 2008 Full Year and Fourth Quarter 11Health News:Wyeth Reports Earnings Results for the 2008 Full Year and Fourth Quarter 12Health News:Wyeth Reports Earnings Results for the 2008 Full Year and Fourth Quarter 13Health News:Wyeth Reports Earnings Results for the 2008 Full Year and Fourth Quarter 14Health News:Saint Joseph's Launches International College of Robotic Surgery 2Health News:Natural Solutions for the Most Depressing Day of the Year 2Health News:Natural Solutions for the Most Depressing Day of the Year 3Health News:Natural Solutions for the Most Depressing Day of the Year 4Health News:Natural Solutions for the Most Depressing Day of the Year 5Health News:Concentric Medical Reaches Important Stroke Milestone 2Health News:Concentric Medical Reaches Important Stroke Milestone 3Health News:BioLife Solutions Announces Record Revenue and Receipt of Funding 2Health News:BioLife Solutions Announces Record Revenue and Receipt of Funding 3
... Trellis Infusion Catheter enables the physician to ... fluid, and disperse the agent by means ... Trellis is a multi-lumen catheter with two ... and infusion holes located between these balloons. ...
... OptiEdge offers design innovations that ensure outstanding ... handling. The biostable acrylic material of the ... the patented OptiEdge is designed to both ... of contact with the posterior capsule; and ...
... posterior chamber lenses are optical implants for ... in the visual correction of aphakia in ... The optical portion consists of a high ... have biconvex optics and supporting haptics of ...
... an intraocular lens that doesn't stop ... natural human lens, the new ACRYSOF® ... high-energy blue light. But while it ... your patient's view. That's just as ...
Medicine Products: